December 13, 2013

Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer


Dec. 13, 2013, 3:33 p.m. EST


PALO ALTO, Calif., Dec. 13, 2013 /PRNewswire via COMTEX/ -- Cellular Biomedicine Group, Inc. (otcqb:CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, is pleased to announce that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

The Phase I clinical trial for TC-DC therapy for HCC is an open-label clinical trial conducted with Shanghai's PLA 85 Hospital, one of China's largest Liver Disease Centers. The trial evaluated the safety and preliminary efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.

"We are very pleased to reach this important milestone in our clinical trial and we look forward to reporting the full data readout early in the new year," said Dr. Wei (William) Cao, PhD, BM, CEO at Cellular Biomedicine Group.

Hepatocellular Carcinoma in China Fifty-five percent (55%) of the world's HCC patients are in China, and there are more than 340,000 new patients diagnosed per year in China, according to the journal titled Chinese Clinical Oncology, Mar 2009, Vol. 14, No. 3. Currently, the most common therapies used to treat most HCC patients are surgery and local chemotherapy, with a 2-year recurrence rate of 51%.

About Cellular Biomedicine Group: Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit:

Forward-Looking Statements: Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.


No comments:

Post a Comment